[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582471":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":65,"collaborators":67,"id":70,"slug":32,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":32,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":32,"enrollmentInfo":78,"targetDuration":32,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":32,"overallStatus":41,"whyStopped":32,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Sunnybrook Health Sciences Centre","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cannabis Arm","EXPERIMENTAL","5:1 CBD:THC oral cannabis",[13],"Drug: Cannabis oil",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Arm","PLACEBO_COMPARATOR","Oral placebo",[19],"Drug: Cannabis placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Cannabis oil","5:1 CBD:THC oral formulation with a concentration of 25 mg\u002Fg CBD and 5 mg\u002Fg THC in a pharmaceutical grade medium chain triglyceride (MCT) oil.",[9],[27],"MPL-005",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Cannabis placebo","Placebo oil",[15],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Mark Boulos, MD","CONTACT","416-480-4473","mark.boulos@sunnybrook.ca",[40,54],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Toronto","Ontario","M4N3M5","Canada",{"type":47,"coordinates":48},"Point",[49,50],-79.39864,43.70643,{"lat":50,"lon":49},[53],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},{"facility":55,"status":41,"city":42,"state":43,"zip":56,"country":45,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},"University Health Network","M5G 2C4",{"type":47,"coordinates":58},[49,50],{"lat":50,"lon":49},[61],{"name":62,"role":36,"phone":63,"phoneExt":32,"email":64},"Hance Clarke, MD","416-340-5164","Hance.Clarke@uhn.ca",{"type":66,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[68],{"name":69,"class":6},"University Health Network, Toronto","100582471",false,"NCT06863740","Using Cannabis to Treat Restless Legs Syndrome","Using Cannabis to Treat Restless Legs Syndrome: A Randomized Placebo Controlled Pilot Safety and Feasibility Trial","Inclusion Criteria:\n\n* ≥25 years of age\n* diagnosis of RLS based on the International RLS Study Group criteria\n* refractory RLS symptoms despite use of dopaminergic and\u002For alpha-2-delta ligand therapy\n* onset of RLS at least 6 months before screening\n\nExclusion Criteria:\n\n* sleep disordered breathing, or sleep disordered breathing that is not adequately controlled on therapy (apnea-hypopnea index of \\>15)\n* cannabis use within 4 weeks of study enrollment\n* known allergy to cannabis, cannabinoids or palm\u002Fcoconut oil\n* Currently pregnant or breast-feeding (a negative urine pregnancy test must be obtained for women of childbearing potential during pretreatment evaluation)\n* Active substance abuse\n* Ischemic heart disease with unstable angina or recent acute coronary syndrome in the last 3 months, uncontrolled arrhythmias, poorly controlled hypertension\n* Serious liver disease\n* History of schizophrenia or any other psychotic disorder","ALL","25 Years",{"count":79,"type":80},30,"ESTIMATED","INTERVENTIONAL",[83],"NA","Restless Legs Syndrome (RLS) is a disorder that causes painful and uncomfortable sensations in the legs, and its symptoms have a significant impact on sleep and quality of life. Cannabis has been used by some RLS patients as a treatment due to its painkilling and drowsiness effects, however there has never been a clinical research trial investigating cannabis in patients with RLS. A controlled trial is needed to establish how safe and feasible cannabis is as a treatment for RLS. The investigators plan to randomize 30 participants with moderate-to-severe RLS to receive either cannabis or placebo for 8 weeks. The investigators will measure patients sleep quality and quality of life at baseline and 8-week follow-up. The investigators will also monitor patients for any adverse reactions to the study drug.",[86],"Restless Leg Syndrome (RLS)","2026-04-22",{"date":89,"type":90},"2026-04-28","ACTUAL",{"date":92,"type":90},"2025-07-25",{"date":94,"type":80},"2027-05",{"name":5,"class":6},2]